The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2025 | Improving access to CAR-T: the Significance of FDA REMS removal
Muhammad Bilal Abid, MD, Texas Tech University Health Sciences Center, Lubbock, TX, discusses the removal of the Risk Evaluation and Mitigation Strategy (REMS) program for CAR-T therapy, stating that it will democratize access, homogenize barriers, and broaden access to CAR-T and cell therapy outside of academic centers. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
